Powered by pioneers.
At Enzene Biosciences, our team of pioneers is dedicated to unlocking the full potential of your biologics and biosimilars.
We only bring the best to your project, and our world-class team has deep scientific and technical expertise across a wide range of modalities to help progress your innovation on its journey to the patients who need it most.
Chief Executive Officer
Dr. Himanshu Gadgil brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization.Dr. Gadgil holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.
Director
Mr. Sandeep Singh joined the Board of Enzene in 2011 and is currently serving the organization as its Director. Mr. Singh has over 20 years of experience in the pharmaceutical industry. He spearheads the domestic as well as the international operations of the Company. In 2016, he was presented with the ‘Emerging Pharma Leader of 2016 Award’ by the Pharma Leaders in association with the Ministry of Health & Family Welfare, Government of India. In 2021, he was featured by ‘ET AND SPENCER STUART 40 under 40’
Independent Director
Ms. Sudha Ravi who joined the Board in 2017 as Independent Director, is a management consultant with over 40 years of banking and non- banking experience in India and USA. In the three decades in State Bank of India (SBI), she has held several important positions including key positions as General Manager, Enterprise Risk Management and as Chief Representative, Washington DC, USA. Working in varied functional areas, including International, Corporate, Retail and Rural banking and at the top echelons of the Bank, has given Ms. Ravi a wide-ranging perspective on business strategy and financial and non-financial sectors of the economy. Later joining the Ajay Piramal Group, Ms. Ravi set up the NBFC- Piramal Finance Ltd and was with the Group’s Financial Services business in various capacities including as CEO/ED/ CCO. She was In-charge of India Venture Advisors Pvt. Ltd., a healthcare and life sciences focused private equity fund sponsored by the Piramal Group. Ms. Ravi has been a member of the CII National Committee on NBFCs and Co-Chairperson, National Council on NBFCs of ASSOCHAM (The Associated Chambers of Commerce and Industry of India). Ms. Ravi has held position as an Independent Director in diverse sectors of the economy – Financial, Pharma, Automobile, Healthcare, Real Estate and continues to do so in many of the same.
Independent Director
Ms. Sangeeta Singh became a member of the Board in 2022 as an Independent Director. She serves as an Independent Director on the boards of several renowned companies. She has over 35 years of experience in Human Resources, Communications and Operations. She was previously a Partner & Head of Human Resources in KPMG India. She holds a Master Degree in Behavioural Psychology and certification in Strategic Human Resource Management from Harvard Business School.
Director
Mr. Aniruddha Singh joined the Board of Enzene in 2025 as Director. Mr. Aniruddha Singh is part of the Chairman and Managing’s Office at Alkem, where he is responsible for developing new ventures, M&A, digitisation initiatives, implementation of strategic programs as well as operational excellence across the organisation. Additionally, he also leads the corporate venture capital initiative at Alkem.
He holds a Master’s degree in Management from the London Business School and a Bachelor’s Degree in Management Studies (Major in Finance) from the University of Mumbai.
Nominee Director
Mr. Prem Pavoor joined the Board of Enzene in 2023 as a Director.
He is Managing Partner, India at Eight Roads Ventures. Mr. Prem was previously based in the United States with McKinsey & Company’s Pharmaceutical and Medical Products Practice where he advised pharmaceutical, consumer healthcare and private equity firms on areas including R&D, business development, manufacturing optimisation and post-merger integrations.
His doctoral thesis work at the Massachusetts Institute of Technology (MIT) and Harvard Medical School focused on implantable medical devices and novel nano-coatings. Prem is the lead author of several scientific publications, the named inventor on two US patents, and a recipient of the MIT-OMNOVA Award for Excellence in Polymer Research and Technology.
Prem holds a Bachelor’s degree in Chemical Engineering from the Institute of Chemical Technology (formerly UDCT), Mumbai, a MS and Ph.D. in Chemical Engineering Practice from MIT and an MBA from MIT Sloan.
Director
Chief Executive Officer
Dr. Himanshu Gadgil brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company.
Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization.
Dr. Gadgil holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.
VP, Global Head of Human Resources
Lata plays a critical role in shaping the organization culture, driving employee engagement and building a high performing workforce. Her extensive experience includes assignments at Cipla, Advinus Therapeutics, Allergan India Pvt. Ltd, Fresenius Kabi.
She holds a BSc. in Microbiology from Ramnarian Ruia College. She also holds a MBA in Human resource management from the SIES College of management studies, India.
Lata leads the design, implementation and execution of HR strategy, organizational design, and development for creating a global organization for Enzene. She also leads EHS efforts in fostering a culture of safety, sustainability and compliance. Additionally, in the business operation role she plays a pivotal part in enhancing the effectiveness, efficiency and impact of the CEO office by executing strategic plans, initiatives, and organizational priorities based on key data analytics and work flows.
Chief Financial Officer
Neel Ambani serves as the Chief Financial Officer at Enzene Biosciences, bringing over 20 years of financial leadership experience across global markets. His expertise spans strategic planning, financial control, risk management, and business transformation.
Prior to joining Enzene, Neel was the Managing Director & AVP at Eli Lilly’s Capability Center
India, where he led the site’s strategic expansion and operational excellence. He also served as CFO at Elanco, overseeing financial operations for the US and EMEA regions, driving significant IBT improvement, and ensuring post-IPO compliance. Earlier in his career, he held key financial roles at Eli Lilly’s Australia and New Zealand offices, as well as its Asia Pacific Treasury operations.
Neel is a Chartered Accountant and holds an MBA from Duke University. He is passionate about building high-performing teams and leveraging financial strategy to drive business growth.
VP, Head of Information Technology
With 25+ years of strategic leadership experience in Information Technology, Kumaresan has led a wide array of initiatives in digital transformation, cybersecurity, infrastructure modernization, application development, operational excellence, and enterprise application systems.
Kumaresan holds a Master of Computer Applications from Bharathidasan University and a Diploma in Computer Science Engineering from the Tamil Nadu Technical Board. He is also certified in CISSP, PMP, and ITIL, and has been consistently recognized in the Top 100 CIO and CSO lists by IDG, along with multiple accolades from Core Media’s CIO Powerlist. Over the course of his career, Kumaresan has held senior IT leadership roles at Unichem Laboratories, DSM Sinochem Pharmaceuticals, Danisco Ingredients India Pvt. Ltd., PVR Limited, and Apex Information Services Pvt. Ltd. In these roles, he led global IT transformations, large-scale ERP implementations, and digital innovation programs that enhanced operational resilience and delivered business value.
As Head of Information Technology, Kumaresan will be focused on strengthening the digital foundation that empowers Enzene teams and will expand the capabilities that help the organization move faster, stay compliant, and deliver smarter manufacturing.
Chief Quality Officer
Dr. Sundar Ramanan brings over 25 years of experience across biopharmaceutical drug development to commercialization lifecycle, with strong emphasis on Quality and Regulatory compliance. His career spans both product development global companies such as Amgen, Baxter and Biocon, and CDMO Just-Evotec biologics. His notable accomplishments include FDA and EMA cGMP approval for manufacturing facilities, advancing regulatory policy with FDA leading to Phase-3 waiver for insulin and thereby enabling the 1st FDA approval for a biosimilar with interchangeability rating without Phase-3 in the US.
Dr. Ramanan is chemical Engineer by training and holds a PhD in Bioengineering from Oregon State University and an MBA from University of Michigan. He is also an accomplished speaker and author. His most recent publication is a book titled “Orphan Drug Development for Rare Disease” RAPS 2021.
As CQO, Sundar will oversee the quality unit in India and lead its expansion into the U.S. market. In India, he will manage the quality operational functions, including QA and QC, while also overseeing the centralized quality system and the quality engineering & validation units.
SVP, Head of Manufacturing Operations
Ravishankar Kasturi is the head of manufacturing operations at Enzene Biosciences. His extensive experience includes assignments at Reliance Life Sciences, as head of manufacturing and process development, followed by Dr. Reddy’s Biologics, and Uni-Sankyo ltd.
Ravi is a biochemical engineer by training with a bachelors in pharmacy. He has also completed executive management from the Indian Institute of Management Bangalore (IIMB), India.
Ravi leads all aspects of manufacturing processes of biologics/biosimilars, forming a diversified portfolio of products which include proteins derived from microbial fermentation and mammalian cell culture.
SVP, US Site Head
With over 25 years in the biopharmaceutical industry, his experience includes progressive leadership roles in Manufacturing, Validation, Quality Assurance, and Network Strategy. Norm has extensive clinical manufacturing experience with mAb and AAV processes, along with commercial experience in mAb drug substance production.
He has been part of 4 successful biopharmaceutical manufacturing facility start-ups. Prior to joining us, Norm served as the Site Head & Head of Biologics Manufacturing at PTC Therapeutics. Before that, he served as Director, Clinical Manufacturing & Business Operations at Bristol-Myers Squibb. Earlier in his career, Norm worked in manufacturing and validation roles at Centocor (J&J) and JRH Biosciences. Norm has Bachelor of Science – Biology from State University of New York – New Paltz.
VP, Head of Process and Analytical Development, Head of CDMO development
Dr. Shilpa Gadgil serves as the head of process, analytical and CDMO development - leading on all project initiatives at Enzene Biosciences. Prior to Enzene, Shilpa was the Head of QC at Intas pharmaceuticals, and has lead the organization in several GMP audits from regulatory authorities such as EMA, USFDA, ANVISA, WHO, MOH, Health Canada, etc.
Shilpa holds a PhD in Biochemistry from University of Tennessee, Memphis. She has vast experience in the field of diabetes and autoimmune diseases from Universities such as UMass, UCLA etc. with over 30 publications in peer reviewed journals.
In here role, she leads end to end development from clone to drug product. She is also the lead for multiple biosimilar products being developed for the EU and US markets.
VP, Global Sales and Marketing
Russell is a results-oriented business development leader with over two decades of experience driving growth in the pharmaceutical and biotech industries. His expertise spans analytical services, formulation development, and manufacturing, providing him with a deep understanding of the drug development process.
Spending over a decade at Catalent Pharma Solutions, he consistently exceeded sales targets and spearheaded strategic initiatives, including the successful reinvigoration of sales in the Northeast region and the design and implementation of a global Inside Sales Group. He has also held leadership roles at Vectura, ANI Pharmaceuticals, and Scotwork, consistently demonstrating his ability to establish companies as leading CDMOs, reinvigorate sales funnels, and streamline operations.
At Enzene, Russell's focus is on forging strategic partnerships and delivering solutions that exceed expectations, driving the company's continued success.
Our growth trajectory is a testament to its strategic vision, resilience and excellence in the biopharmaceutical industry. Having achieved significant milestones in a short span of time, we have made impactful advancements, showcasing our commitment to innovation, quality, and global reach.
A global CDMO and biosimilar developer dedicated to realizing your vision.
Through a passionately progressive approach designed just for you, our cutting-edge services and productive pipeline of biosimilars cater to your project’s every need. By continuously innovating and pushing boundaries, we strive to maximize your return on investment and help you bring trusted and affordable medicines to market at speed.
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.